XML 33 R17.htm IDEA: XBRL DOCUMENT v3.25.4
Stockholders' Equity
 12 Months Ended
Dec. 26, 2025
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
Warrants

In connection with an acquisition during fiscal 2022, the Company issued warrants with a fair value of $1,701 to purchase up to 150,000 shares of the Company’s common stock at an exercise price of $31.55 per share. The warrants have been fully exercised and there are no warrants outstanding as of December 26, 2025.

2023 Employee Stock Purchase Plan

In fiscal 2023, the Company’s stockholders adopted the Company’s Employee Stock Purchase Plan (the “ESPP”), which permits eligible employees to purchase a total of approximately 793,000 shares of the Company’s common stock through payroll deductions of up to 10% of eligible compensation. The purchase price of the shares will be 85% of the fair market value of the common stock on the date of purchase. The plan does not include any look-back or reset provisions. The offering periods run bi-annually from January 1st to June 30th and July 1st to December 31st. At December 26, 2025, there were approximately 731,000 shares of common stock available for issuance under the ESPP. The ESPP did not have a material impact on the Company’s consolidated financial statements in the fiscal years presented. The Company may amend, suspend or terminate the ESPP at any time.

Equity Incentive Plan
 
On May 17, 2019, the Company’s stockholders approved the 2019 Omnibus Equity Incentive Plan (the “2019 Plan”). The purpose of the 2019 Plan is to promote the interests of the Company and its stockholders by (i) attracting and retaining key officers, employees and directors of, and consultants to, the Company and its Subsidiaries and Affiliates; (ii) motivating such individuals by means of performance-related incentives to achieve long-range performance goals; (iii) enabling such individuals to participate in the long-term growth and financial success of the Company; (iv) encouraging ownership of stock in the Company by such individuals; and (v) linking their compensation to the long-term interests of the Company and its stockholders.

The 2019 Plan is administered by the Compensation and Human Capital Committee (the “Committee”) of the Board of Directors and allows for the issuance of stock options, stock appreciation rights (“SARs”), RSAs, RSUs, performance awards, or other stock-based awards. Stock option exercise prices are fixed by the Committee but shall not be less than the fair market value of a common share on the date of the grant of the option, except in the case of substitute awards. Similarly, the grant price of an SAR may not be less than the fair market value of a common share on the date of the grant. The Committee will determine the expiration date of each stock option and SAR, but in no case shall the stock option or SAR be exercisable after the expiration of 10 years from the date of the grant. The 2019 Plan provides for 4,230,000 shares available for grant. As of December 26, 2025, there were 1,543,550 shares available for grant.
 
Stock compensation expense was $21,242, $17,778 and $20,042 for the fiscal years ended December 26, 2025, December 27, 2024 and December 29, 2023, respectively. The related tax (benefit) expense for stock-based compensation was $(3,570), $(211) and $580 for the fiscal years ended December 26, 2025, December 27, 2024 and December 29, 2023, respectively.

The following table reflects the activity of RSAs and RSUs during the fiscal year ended December 26, 2025:
Time-BasedPerformance-BasedMarket-Based
SharesWeighted Average
Grant Date Fair Value		SharesWeighted Average
Grant Date Fair Value		SharesWeighted Average
Grant Date Fair Value
Unvested at December 27, 2024483,284 $35.68 881,500 $34.79 303,036 $30.04 
Granted219,968 63.35 740,294 63.03 35,101 61.16 
Vested(217,915)35.02 (164,601)32.47 (162,351)29.12 
Forfeited(14,471)42.05 (149,880)33.52 — — 
Unvested at December 26, 2025470,866 $48.71 1,307,313 $51.22 175,786 $37.10 

The fair value of RSAs and RSUs vested during the fiscal years ended December 26, 2025, December 27, 2024 and December 29, 2023, was $17,173, $18,370 and $7,170, respectively.

The Company granted 995,363 RSAs and RSUs to its employees and directors at a weighted average grant date fair value of $63.04 during the fiscal year ended December 26, 2025. These awards are a mix of time-, market- and performance-based grants awarded to key employees and non-employee directors that generally vest over a range of periods up to five years. The market- and performance-based RSAs and RSUs generally cliff vest, if at all, after the conclusion of a three-year performance period and vesting is subject to the award recipient’s continued service to the Company as of the vesting date. The number of performance-based RSAs and RSUs that ultimately vest is based on the Company’s attainment of certain profitability and return on invested capital targets.

At December 26, 2025, the total unrecognized compensation cost for the unvested RSAs and RSUs was $25,769 to be recognized over a weighted-average period of approximately 1.7 years. Of this total, $15,024 related to awards with time-based vesting provisions to be recognized over a weighted average period of 1.6 years and $10,745 related to awards with performance- or market-based vesting provisions to be recognized over a weighted average period of 1.7 years.

The following table summarizes stock option activity during the fiscal year ended December 26, 2025:
SharesWeighted
Average
Exercise Price		Aggregate
Intrinsic
Value		Weighted Average
Remaining Contractual
Term (in years)
Outstanding December 27, 2024100,876 $20.23 $2,870 1.1
Outstanding December 26, 2025100,876 $20.23 $4,368 0.2
Exercisable at December 26, 2025100,876 $20.23 $4,368 0.2

The total intrinsic value of options exercised during fiscal 2024 and 2023 was $194 and $22, respectively. There were no option exercises in fiscal 2025. The Company issues new shares upon the exercise of stock options. No stock option expense was recognized during the fiscal years ended December 26, 2025, December 27, 2024 and December 29, 2023.

In connection with an acquisition, the Company issued stock awards to certain members of the acquiree’s management team which were classified as liabilities. These awards vest over a period of up to four years. Stock-based compensation expense for these awards was $2,634, $2,175 and $2,175 during the fiscal years ended December 26, 2025, December 27, 2024 and December 29, 2023, respectively. As of December 26, 2025 and December 27, 2024, the fair value of these awards was $7,347 and $4,712, respectively, and they are presented within accrued liabilities on the Company’s consolidated balance sheets.

Performance-Based Restricted Share Units

In February 2025, the Company’s Board of Directors approved a grant of a total of 541,375 PRSUs to certain of the Company’s officers and employees under the Company’s 2019 Plan. These grants are included in the performance-based column of the RSAs and RSUs activity table above. The PRSUs, which have a four-year term from the date of grant, are subject to service and
performance conditions and will only become vested and payable to the extent that a qualifying change in control occurs during the four-year period. The fair value of these awards was $22,235, which was determined using a Monte Carlo simulation in order to model a range of possible future stock prices for the Company’s common stock. No share-based compensation expense has been recorded in fiscal 2025 for these PRSUs.

Share Repurchase Program

In November 2023, the Company announced a two-year share repurchase program in an amount up to $100,000. The share repurchase program ended in December 2025 with a total of 667,433 shares of the Company’s common stock repurchased for $32.4 million.